Clinical trial
Phase 2 Study (With Safety Lead in) of the Safety, Tolerability and Efficacy of Anti-CTLA4 (Ipilimumab) and Anti-PD-1 (Nivolumab) in Combination With Radiation Therapy to 50-66 Gy in Low-Intermediate Volume, Local-Regionally Advanced HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
NCT03799445 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study (With Safety Lead in) of the Safety, Tolerability and Efficacy of Anti-CTLA4 (Ipilimumab) and Anti-PD-1 (Nivolumab) in Combination With Radiation Therapy to 50-66 Gy in Low-Intermediate Volume, Local-Regionally Advanced HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 25, 2019
- Completion date
- April 14, 2026
- Enrollment
- 37 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage i hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, clinical stage ii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, human papillomavirus positive oropharyngeal squamous cell carcinoma, oropharyngeal basaloid carcinoma, pathologic stage i hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, pathologic stage ii hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, posterior tongue squamous cell carcinoma, soft palate squamous cell carcinoma, stage iii oropharyngeal squamous cell carcinoma ajcc v7, stage iva oropharyngeal squamous cell carcinoma ajcc v7, tonsillar squamous cell carcinoma